Your browser doesn't support javascript.
loading
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels, Sebastian; Massutí, Bartomeu; Schildhaus, Hans-Ulrich; Franklin, Jeremy; Sebastian, Martin; Felip, Enriqueta; Grohé, Christian; Rodriguez-Abreu, Delvys; Abdulla, Diana S Y; Bischoff, Helge; Brandts, Christian; Carcereny, Enric; Corral, Jesús; Dingemans, Anne-Marie C; Pereira, Eva; Fassunke, Jana; Fischer, Rieke N; Gardizi, Masyar; Heukamp, Lukas; Insa, Amelia; Kron, Anna; Menon, Roopika; Persigehl, Thorsten; Reck, Martin; Riedel, Richard; Rothschild, Sacha I; Scheel, Andreas H; Scheffler, Matthias; Schmalz, Petra; Smit, Egbert F; Limburg, Meike; Provencio, Mariano; Karachaliou, Niki; Merkelbach-Bruse, Sabine; Hellmich, Martin; Nogova, Lucia; Büttner, Reinhard; Rosell, Rafael; Wolf, Jürgen.
Afiliación
  • Michels S; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Massutí B; Department of Oncology, Alicante University Hospital-ISABIAL, Alicante, Spain.
  • Schildhaus HU; Institute of Pathology, University Hospital Goettingen, Göttingen, Germany and Targos Molecular Pathology, Kassel, Germany.
  • Franklin J; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Cologne, Germany.
  • Sebastian M; Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
  • Felip E; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Grohé C; Department of Pneumology, Protestant Lung Hospital Berlin, Berlin, Germany.
  • Rodriguez-Abreu D; Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
  • Abdulla DSY; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Bischoff H; Thoraxonkologie, Thoraxklinik, Heidelberg, Germany.
  • Brandts C; Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
  • Carcereny E; Servei d'Oncologia Mèdica, Institut Català d'Oncologia Badalona-Hospital Germans Trias i Pujol, Carretera de Canyet, Badalona, Spain.
  • Corral J; Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain; prior affiliation during the trial: Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Dingemans AC; Department for Oncology, Maastricht University Medical Center, Maastricht, Netherlands.
  • Pereira E; Spanish Lung Cancer Group, Barcelona, Spain.
  • Fassunke J; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Fischer RN; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Gardizi M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Heukamp L; Institute of Hematopatholgy Hamburg, Hamburg, Germany, and Lung Cancer Network NOWEL, Oldenburg, Germany.
  • Insa A; Hospital Clínico Universitario de Valencia, València, Spain.
  • Kron A; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Menon R; NEO New Oncology GmbH, Cologne, Germany.
  • Persigehl T; Department of Radiology, University Hospital Cologne, Cologne, Germany.
  • Reck M; Department for Thoracic Oncology, Airway Research Center North (ARCN), German Center for Lung Research, LungenClinic Grosshansdorf, Großhansdorf, Germany.
  • Riedel R; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Rothschild SI; University Hospital Basel, Department Internal Medicine, Medical Oncology, Basel, Switzerland.
  • Scheel AH; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Schmalz P; Clinical Trials Centre Cologne (CTCC) Medical Faculty, University of Cologne, Cologne, Germany.
  • Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Limburg M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Provencio M; Department of Medical Oncology, Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Spain.
  • Karachaliou N; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain.
  • Merkelbach-Bruse S; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Hellmich M; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Cologne, Germany.
  • Nogova L; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Büttner R; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
  • Rosell R; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany. Electronic address: juergen.wolf@uk-koeln.de.
J Thorac Oncol ; 14(7): 1266-1276, 2019 07.
Article en En | MEDLINE | ID: mdl-30978502
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Proteínas Tirosina Quinasas / Reordenamiento Génico / Proteínas Proto-Oncogénicas / Carcinoma de Pulmón de Células no Pequeñas / Inhibidores de Proteínas Quinasas / Crizotinib / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Idioma: En Revista: J Thorac Oncol Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Proteínas Tirosina Quinasas / Reordenamiento Génico / Proteínas Proto-Oncogénicas / Carcinoma de Pulmón de Células no Pequeñas / Inhibidores de Proteínas Quinasas / Crizotinib / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Idioma: En Revista: J Thorac Oncol Año: 2019 Tipo del documento: Article